首页> 外文OA文献 >Application of Anti-PD-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer

【2h】

Application of Anti-PD-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer

机译：抗PD-L1单克隆抗体atezolizumab在常见尿路上膀胱癌中的应用

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
S.S. Sidorova; D.M. Ponomarenko; D.Yu. Yukalchuk; S.P. Sidorov; Ye.A. Rybkina; Z.V. Dyakonenko; Ye.V. Seredkin; O.V. Baklanova;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) [J] . Thomas Powles, Dorothee Nickles, Eliezer Van Allen, Journal for ImmunoTherapy of Cancer . 2015,第S2期

机译：在晚期尿路上皮膀胱癌（UBC）中与atezolizumab（MPDL3280a;抗PD-L1）的临床获益相关的免疫生物标记物
2. CLINICAL APPLICATION OF MONOCLONAL ANTIBODY-DRUG CONJUGATE TO IMMUNOTARGETING CHEMOTHERAPY OF BLADDER CANCER [J] . Li Longcheng, Zhang Yongshang, Lin Qiao, Chinese Medical Journal . 1995,第10期

机译：单克隆抗体药物结合物在膀胱癌免疫靶向治疗中的临床应用
3. CLINICAL APPLICATION OF MONOCLONAL ANTIBODY-DRUG CONJUGATE TO IMMUNOTARGETING CHEMOTHERAPY OF BLADDER CANCER [J] . 李龙承, 章咏裳, 林乔, 中华医学杂志：英文版 . 1995,第010期

机译：单克隆抗体 - 药物缀合物对膀胱癌免疫靶向化疗的临床应用
4. Generation of Novel Anti-CLDN18.2 Monoclonal Antibodies as Therapies for Gastric and Pancreatic Cancer [C] . Richard Zhang, Haishan Lin, Andrew Wong, Protein Engineering Summit. . 2018

机译：生成新型抗CLDN18.2单克隆抗体作为胃癌和胰腺癌的疗法
5. Treatment patterns, costs and outcomes of systemic chemotherapy, adjuvant intravesical therapy, and surveillance for urothelial bladder cancer. [D] . Kerrigan, Matthew Charles. 2007

机译：全身化疗，辅助膀胱内治疗和尿路上皮膀胱癌监测的治疗方式，费用和结果。
6. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) [O] . Thomas Powles, Dorothee Nickles, Eliezer Van Allen, 2015

机译：在晚期尿路上皮膀胱癌（UBC）中与atezolizumab（MPDL3280a;抗PD-L1）的临床获益相关的免疫生物标记物
7. Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) [O] . Thomas Powles, Dorothee Nickles, Eliezer Van Allen, 2015

机译：在晚期尿路上皮膀胱癌（UBC）中与atezolizumab（MPDL3280a;抗PD-L1）的临床获益相关的免疫生物标记物
8. Monoclonal Antibodies and Cancer. Studies on the Use of Monoclonal Antibodies for Imaging and Therapy of Cancer, with Special Emphasis on Ovarian Carcinoma [R] . Haisma, H. J. 1987

机译：单克隆抗体和癌症。单克隆抗体在癌症成像和治疗中的应用研究，特别强调卵巢癌

Application of Anti-PD-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer

著录项

引文网络

相似文献

相关主题

期刊订阅